Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism

Plain-language guide to PMID 24948345 (2014): crossover randomized controlled trial study of Parathyroid Hormone (PTH 1-84).

Key Facts

PMID: 24948345
Journal: The Journal of pediatrics
Year: 2014
Study type: Randomized Controlled Trial
Authors: Winer KK et al. (4 authors)
DOI: 10.1016/j.jpeds.2014.04.060
Registered trial: NCT00743782

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

To compare the response with synthetic human parathyroid hormone (PTH) 1-34 delivered by twice-daily injection vs insulin pump in children with severe congenital hypoparathyroidism due to calcium receptor mutation or autoimmune polyglandular syndrome type 1.

Who Took Part

By PubMed's age tags, the people studied were children, teenagers and young adults, both men and women.

Children and young adults aged 7-20 years with congenital hypoparathyroidism (N = 12) were randomized to receive PTH 1-34, delivered either by twice-daily subcutaneous injection or insulin pump for 13 weeks, followed by crossover to the opposite delivery method.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Parathyroid Hormone (PTH 1-84) and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 13 weeks.

The principal outcome measures were serum and urine calcium levels.

Secondary outcomes included serum and urine magnesium and phosphate levels and bone turnover markers.

What Was Measured

The subject headings attached to it are Hypoparathyroidism, Infusion Pumps and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized and crossover study of Parathyroid Hormone (PTH 1-84) over 13 weeks.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (The Journal of pediatrics), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page.

Our Notes on the Compound

Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.

Parathyroid Hormone (PTH 1-84) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.